[1]尚依一 刘罗 庞明杰 张艳.基因检测在肥厚型心肌病中的应用进展[J].心血管病学进展,2021,(6):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
 SHANG Yiyi,LIU Luo,PANG Mingjie,et al.Gene Detection for Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(6):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
点击复制

基因检测在肥厚型心肌病中的应用进展()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年6期
页码:
512
栏目:
综述
出版日期:
2021-06-25

文章信息/Info

Title:
Gene Detection for Hypertrophic Cardiomyopathy
作者:
尚依一1 刘罗1 庞明杰 2张艳3
(1. 昆明理工大学医学院 昆明理工大学附属医院,云南 昆明650000;2. 云南省第一人民医院心内科,云南 昆明650000;3. 云南省第一人民医院磁共振影像科,云南 昆明 650000)
Author(s):
SHANG Yiyi1LIU Luo1 PANG Mingjie2ZHANG Yan3
(1.Kunming University of Science and Technology School of Medicine,Affiliated Hospital of Kunming University of Science and Technology,Kunming 650032,Yunnan,china;2. Department of Cardiology, The First People’s Hospital of Yunnan Province,Kunming,650032,china;3. Department of Magnetic Resonance Imaging, The First People’s Hospital of Yunnan Province,Kunming 650032,Yunnan,china)
关键词:
肥厚型心肌病基因突变检测方法
Keywords:
Hypertrophic cardiomyopathyGene mutationDetection method
DOI:
10.16806/j.cnki.issn.1004-3934.2021.06.009
摘要:
肥厚型心肌病(HCM)是常见的遗传性心血管疾病之一,发病隐匿,预后差异大,是青少年心源性猝死的主要原因。近年来随着HCM病理生理机制研究深入及基因工程技术的发展,其治疗则向分子靶向药物及基因治疗方向转变。本文分析了HCM的致病突变基因,明确基因检测对于HCM的重要指导作用,归纳并总结了近年来对于HCM的基因检测方法。
Abstract:
Hypertrophic cardiomyopathy (HCM) is one of the common hereditary cardiovascular diseases, with hidden onset and large prognostic differences. It is the main cause of sudden cardiac death in adolescents. In recent years, with the in-depth study of the pathophysiological mechanism of HCM and the development of genetic engineering technology, its treatment has shifted to molecular targeted drugs and gene therapy. This article analyzes the pathogenic mutation genes of HCM, clarifies the important guiding role of genetic testing for HCM, and summarizes and summarizes the genetic testing methods for HCM in recent years

参考文献/References:

[1]庞明杰,丁筱雪,张艳,等. 云南省一家族性肥厚型心肌病家系的基因筛查及临床特征分析[J]. 中华心血管病杂志,2018,46(11):887-891.

[2] Maron BJ,Estes NA 3rd,Maron MS,et al. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy[J]. Circulation,2003,107(23):2872-2875.

[3] de Gregorio C,Andò G. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors: a word of comfort to younger patients? [J] . Am J Cardiol,2014,114(3):500-501.

[4]陶阳,褚志刚. 肥厚型心肌病心肌MRI延迟强化的研究进展[J]. 解放军医学杂志,2018,43(8):80-85.

[5] McKenna WJ,Maron BJ,Thiene G. Classification,epidemiology,and global burden of cardiomyopathies[J]. Circ Res,2017,121(7):722-730.

[6]曹博涵,吴光哲. 肥厚型心肌病研究进展[J]. 临床军医杂志,2020(4):469-471.

[7]陆静. 肥厚型心肌病的临床表现及心电图特点[J]. 影像研究与医学应用,2020,4(4):191-192.

[8] Authors/Task Force members,Elliott PM,Anastasakis A,et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC) [J] . Eur Heart J,2014,35(39):2733-2779.

[9]黄蕾,秦显雨,吴岳恒,等. 肥厚型心肌病相关基因的生物信息学分析[J]. 岭南心血管病杂志,2020,26(1):97-103.

[10] Geisterfer-Lowrance AA,Kass S,Tanigawa G,et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation[J]. Cell,1990,62(5):999-1006.

[11] Maron BJ,Maron MS,Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives[J]. J Am Coll Cardiol,2012,60(8):705-715.

[12] Watkins H,Conner D,Thierfelder L,et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy[J]. Nat Genet,1995,11(4):434-437.

[13] Burke MA,Cook SA,Seidman JG,Seidman CE. Clinical and mechanistic insights into the genetics of cardiomyopathy[J]. J Am Coll Cardiol,2016,68(25):2871-2886.

[14]袁华苑,郭涛. 肥厚型心肌病基因学研究进展[J]. 岭南心血管病杂志,2019,25(5):106-109.

[15] Purushotham G,Madhumohan K,Anwaruddin M,et al. The MYH7 p.R787H mutation causes hypertrophic cardiomyopathy in two unrelated families[J]. Exp Clin Cardiol,2010,15(1):e1-e4.

[16] Akhtar M,Elliott P. The genetics of hypertrophic cardiomyopathy[J]. Glob Cardiol Sci Pract,2018,2018(3):36.

[17] Pasquale F,Syrris P,Kaski JP,et al. Long-term outcomes in hypertrophic cardiomyopathy caused by mutations in the cardiac troponin T gene [J]. Circ Cardiovasc Genet,2012,5(1):10-17.

[18] Sohn DW,Kim HK,Kim YJ,et al. Erratum: Cardiomyopathies with mixed and inapparent morphological features in cardiac troponin I3 mutation[J]. Korean Circ J,2017,47(4):540.

[19] Khouzam A,Kwan A,Baxter S,et al. Factors associated with uptake of genetics services for hypertrophic cardiomyopathy[J]. J Genet Couns,2015,24(5):797-809.

[20] Richards S,Aziz N,Bale S,et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med,2015,17(5):405-424.

[21] Hershberger RE,Givertz MM,Ho CY,et al. Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG) [J]. Genet Med,2018,20(9):899-909.

[22] Alfares AA,Kelly MA,McDermott G,et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity [J]. Genet Med,2015,17(11):880-888.

[23] Robyns T,Breckpot J,Nuyens D,et al. Clinical and ECG variables to predict the outcome of genetic testing in hypertrophic cardiomyopathy[J]. Eur J Med Genet,2020,63(3):103754.

[24] Pett KD,Willett WC,Vartiainen E,et al. The seven countries study[J]. Eur Heart J,2017,38(42):3119-3121.

[25] Charron P,Dubourg O,Desnos M,et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene[J]. Circulation,1998,97(22):2230-2236.

[26]张智文,王婷,杨海涛. 肥厚型心肌病家系携带ACTN2,MYBPC3和TNNI3基因突变分析[J]. 临床心血管病杂志,2020,36,No.320(2):75-78.

[27] Walsh R,Mazzarotto F,Whiffin N,et al. Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathy[J]. Genome Med,2019,11(1):5.

[28]王玉鑫,张世梅,闵婷婷,等. 肥厚型心肌病致病基因热点突变位点Taqman-MGB探针检测方法的建立[J]. 中国生物化学与分子生物学报,2020,36(5):117-125.

[29] Olivotto I,d’Amati G,Basso C,et al. Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations[J]. Cardiovasc Res,2015,105(4):409-423.

[30] Rubattu S,Bozzao C,Pennacchini E,et al. A next-generation sequencing approach to identify gene mutations in early- and late-onset hypertrophic cardiomyopathy patients of an Italian cohort[J]. Int J Mol Sci,2016,17(8):1239.

[31] Seo J,Kim M,Hong GR,et al. Fabry disease in patients with hypertrophic cardiomyopathy: a practical approach to diagnosis[J]. J Hum Genet,2016,61(9):775-780.

[32] Viola HM,Hool LC. Impaired calcium handling and mitochondrial metabolic dysfunction as early markers of hypertrophic cardiomyopathy[J]. Arch Biochem Biophys,2019,665:166-174.

[33] Xiao X,Zhang J,Gong J,et al. Rapid detection of Pseudomonas aernginosa by the fluorescence quantitative TaqMan PCR assay targetting ETA gene[J].Sheng Wu Gong Cheng Xue Bao,2008,24(4):581-585.

[34] Zhang Y,Qu S,Zhao J,et al. A novel RFLP-ARMS TaqMan PCR-based method for detecting the BRAF V600E mutation in melanoma[J]. Oncol Lett,2018,16(2):1615-1621.

[35] van der Heyden H,Wallon T,Lévesque CA,et al. Detection and quantification of Pythium tracheiphilum in soil by multiplex real-time qPCR[J]. Plant Dis,2019,103(3):475-483.

[36] Zhang Z,Liu D,Sun W,et al. Multiplex one-step Real-time PCR by Taqman-MGB method for rapid detection of pan and H5 subtype avian influenza viruses[J]. PLoS One,2017,12(6):e0178634.

[37] Yang F,Chen B,Liu F,et al. Development of a TaqMan MGB RT-PCR assay for the detection of type A and subtype H10 avian influenza viruses[J]. Arch Virol,2018,163(9):2497-2501.

相似文献/References:

[1]冯坤,刘春霞,熊峰,等.超声心动图在肥厚型心肌病诊治中的应用进展[J].心血管病学进展,2016,(4):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
 FENG Kun,LIU Chunxia,XIONG Feng,et al.Progress in Application of Echocardiography in Diagnosis and Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2016,(6):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
[2]黄淮滨 刘甲兴.肥厚型心肌病治疗新靶点——钙脱敏治疗[J].心血管病学进展,2019,(7):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
 HUANG HuaibinLIU Jiaxing.A Novel Target for Therapy in Hypertrophic Cardiomyopathy: Ca2+ desensitizer[J].Advances in Cardiovascular Diseases,2019,(6):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
[3]占小锋 张长磊 李刚.β肾上腺素受体阻滞剂对甘油三酯代谢的影响及其作用机制的阐述[J].心血管病学进展,2019,(9):1298.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.029]
 ZHAN Xiaofeng,ZHANG Changlei,LI Gang.Effect of -adrenergic Receptor Blockers on Triglyceride Metabolism and Mechanism[J].Advances in Cardiovascular Diseases,2019,(6):1298.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.029]
[4]谭莹 易龙 谢峻 徐标 陆剑嵘.一个家族肥厚心肌病的遗传学分析[J].心血管病学进展,2020,(8):880.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.023]
 TAN Ying,YI Long,XIE Jun,et al.Genetic Analysis of A Familial Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(6):880.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.023]
[5]马秀英 贾锋鹏.肥厚型心肌病并发心房颤动的危险因素研究进展[J].心血管病学进展,2020,(12):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
 MA XiuyingJIA Fengpeng.Update about the Risk Factors of Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(6):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
[6]陈秀 陈甘潇 张中和 胡丹 夏豪.钙通道突变致早期复极综合征的电生理机制研究[J].心血管病学进展,2021,(5):457.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.018]
 CHEN Xiu,CHEN Ganxiao,ZHANG Zhonghe,et al.Electrophysiological Mechanism of Early Repolarization Syndrome Caused by Calcium Channel Mutation[J].Advances in Cardiovascular Diseases,2021,(6):457.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.018]
[7]邓清文,何森.肥厚型心肌病合并心房颤动的研究进展[J].心血管病学进展,2021,(4):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
 DENG Qingwen,HE Sen.Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(6):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
[8]王娟 杨艳敏.肥厚型心肌病发生缺血性卒中的危险因素和管理策略研究进展[J].心血管病学进展,2021,(7):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
 WANG Juan,YANG Yanmin.Risk Factors and Management Strategies of Ischemic Stroke in Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(6):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
[9]武志刚 孙佳莉 王巍.基于心脏磁共振成像的肥厚型心肌病患者早期峰值充盈率与舒张功能相关性的研究[J].心血管病学进展,2021,(7):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
 WU Zhigang,SUN Jiali,WANG Wei.Correlation Between Early Peak Filling Rate and Diastolic Function in Patients with Hypertrophic Cardiomyopathy Based on Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2021,(6):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
[10]马宗宾 赵永辉 刘倩玲 张智文.家族性心房颤动家系携带NEXN和JPH2基因突变分析[J].心血管病学进展,2021,(7):663.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.021]
 MA Zongbin,ZHAO Yonghui,LIU Qianling,et al.Mutation Analysis of NEXN and JPH2 Genes in a Family with Familial Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(6):663.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.021]

备注/Memo

备注/Memo:
通讯作者:庞明杰,Email:1836443709@qq.com
更新日期/Last Update: 2021-07-23